Manufacturing and Supply, page-34

Avanir comprehensively reevaluated the U.S. migraine medication market. As a result, the decision was made to terminate the licensing agreement¹.

Optinose (NASDAQ:OPTN), received written notice from Avanir Pharmaceuticals, Inc. of its election to terminate the License Agreement to develop and commercialize ONZETRA® XSAIL® (Sumatriptan) in the United States, Canada, and Mexico. As a result, the License Agreement is expected to terminate on March 10, 2019².

Through September 30, 2018, under the terms of the License Agreement with Avanir, Optinose has received aggregate cash payments of $70 million in connection with the initial signing and subsequent payments².

1 https://www.otsuka.co.jp/en/company/newsreleases/2018/20181211_1.html
2 https://globenewswire.com/news-rele...Avanir-Pharmaceuticals-for-ONZETRA-XSAIL.html